VIRX
Closed
Viracta Therapeutics Inc
0.241
0.000 (0.00%)
Last Update: 06 Sep 2024 23:00:00
Yesterday: 0.241
Day's Range: 0.2222 - 0.2479
Send
sign up or login to leave a comment!
When Written:
1.45
Viracta Therapeutics Inc is a clinical-stage biotechnology company based in San Diego, California. The company is focused on the development of innovative therapies for the treatment of viral-associated cancers, including Epstein-Barr virus (EBV)-associated lymphomas and nasopharyngeal carcinoma (NPC).
Viracta's lead product candidate, nanatinostat, is an orally administered small molecule inhibitor of histone deacetylases (HDACs) that is being developed as a combination therapy with valganciclovir for the treatment of EBV-associated lymphomas and NPC.
The company is also developing a pipeline of other small molecule inhibitors targeting various pathways involved in viral-associated cancers, including the PI3K/AKT/mTOR pathway and the Wnt/β-catenin pathway.
Viracta has partnerships with several academic institutions and research organizations, including the National Cancer Institute and the University of California, San Diego. The company is backed by a group of leading venture capital firms and has raised over $100 million in funding to date.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Viracta's lead product candidate, nanatinostat, is an orally administered small molecule inhibitor of histone deacetylases (HDACs) that is being developed as a combination therapy with valganciclovir for the treatment of EBV-associated lymphomas and NPC.
The company is also developing a pipeline of other small molecule inhibitors targeting various pathways involved in viral-associated cancers, including the PI3K/AKT/mTOR pathway and the Wnt/β-catenin pathway.
Viracta has partnerships with several academic institutions and research organizations, including the National Cancer Institute and the University of California, San Diego. The company is backed by a group of leading venture capital firms and has raised over $100 million in funding to date.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!